What is MapLight Therapeutics, Inc. 's free cash flow?

MapLight Therapeutics, Inc. (MPLT) reported free cash flow of -$51.2M in Q1 2026.

What does free cash flow mean?

Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.

MapLight Therapeutics, Inc. MPLT Free cash flow

Free cash flow at other companies

Bristol-Myers SquibbBMY

$757M-55.3%

Johnson & JohnsonJNJ

$1.47B-56.6%

Acadia PharmaceuticalsACAD

$28.77M+41.6%

AbbVieABBV

$3.56B+155%

LBR

LB Pharmaceuticals Inc Common StockLBRX

-$23.32M-186%

Neurocrine BiosciencesNBIX

——

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Valuation

See full

Market cap$1.39B—

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Calculated from MapLight Therapeutics, Inc. ’s reported figures.

−$51.2Mnet cash from operating−$24.0Kcapital expenditures=-$51.2M

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's free cash flow?: MapLight Therapeutics, Inc. (MPLT) reported free cash flow of -$51.2M in Q1 2026.
What does free cash flow mean?: Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.